Lymphangioleiomyomatosis, almost always called LAM, is a progressive lung disease in which abnormal smooth-muscle-like cells infiltrate the lungs and destroy healthy tissue, leaving behind thin-walled air-filled cysts. It overwhelmingly affects women of childbearing age, occurs in two forms linked to mutations in the same pair of genes, and went largely untreatable until the past decade or so. The disease is rare enough that many physicians have never encountered a case, yet advances in both diagnosis and drug therapy have reshaped the outlook for people living with it.
Two Forms, One Genetic Root
LAM comes in two varieties. Sporadic LAM strikes otherwise healthy women with no family history of the disease. The second form, TSC-LAM, shows up in people who already have tuberous sclerosis complex, a genetic condition that causes benign tumors in multiple organs. Both forms trace back to mutations in the TSC1 or TSC2 genes, which normally act as brakes on a cellular growth pathway called mTORC1. When those brakes fail, the pathway runs unchecked, driving the abnormal cells to grow, survive, and resist the body’s normal cleanup processes.1PubMed Central. Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis The distinction between sporadic and TSC-associated LAM matters clinically because TSC-LAM patients tend to be diagnosed younger and have additional organ involvement from tuberous sclerosis itself.2PubMed. Natural history of incidental sporadic and tuberous sclerosis complex associated lymphangioleiomyomatosis
Why LAM Is Almost Exclusively a Women’s Disease
The near-total restriction of LAM to women is one of its defining puzzles, and estrogen appears to be the central answer. LAM cells carry estrogen and progesterone receptors, and lung function in affected women tends to decline during periods when estrogen levels are high.3PubMed Central. Minireview: Lymphangioleiomyomatosis (LAM): The “Other” Steroid-Sensitive Cancer Menstruation, pregnancy, and estrogen-containing medications can all trigger a sudden worsening of symptoms.4PubMed Central. Novel developments in the study of estrogen in the pathogenesis and therapeutic intervention of lymphangioleiomyomatosis Laboratory work has shown that estrogen promotes the survival and spread of TSC2-deficient cells to the lungs, and adding progesterone to the mix appears to amplify the effect.5PubMed Central. Progesterone and estradiol synergistically promote the lung metastasis of tuberin-deficient cells in a preclinical model of lymphangioleiomyomatosis The rare cases of LAM reported in men have occurred almost entirely in the setting of tuberous sclerosis, where the genetic driver is so strong it can operate without estrogen doing the heavy lifting.
A Cancer That Starts in the Uterus
For years, researchers debated where LAM cells originate. The lungs seemed like the obvious answer, but the biology never quite fit. A growing body of evidence now points to the uterus. In mouse models, knocking out the TSC2 gene specifically in uterine muscle cells produced tumors that eventually appeared in the lungs, suggesting the cells migrated there from the uterus.6Molecular Endocrinology. Uterine-Specific Loss of Tsc2 Leads to Myometrial Tumors in Both the Uterus and Lungs Single-cell sequencing of LAM lesions removed from human lungs confirmed that the abnormal cells look nothing like normal lung cells. Instead, they share their closest genetic signature with cells from the uterus and neural crest.7bioRxiv. Identification of the lymphangioleiomyomatosis cell and its uterine origin
This reframes LAM as something closer to a low-grade metastasizing cancer than a purely lung-based disease. The “LAM cell” also bears a strong resemblance to a family of tumors called PEComas, and one theory holds that renal angiomyolipomas, benign kidney tumors that frequently accompany LAM, may even serve as a source of cells that seed the lungs.8PubMed Central. Pulmonary lymphangioleiomyomatosis associated with aggressive renal angiomyolipoma Whether the cells start in the uterus, the kidney, or both, the picture of LAM as a systemic disease with lung-dominant symptoms is now well established.
How LAM Feels and Presents
The lung symptoms tend to dominate. The most common presentations are progressive breathlessness on exertion, collapsed lungs (pneumothorax), and milky fluid collections in the chest called chylous pleural effusions.9European Respiratory Journal. Lymphangioleiomyomatosis Patients themselves describe shortness of breath and crushing fatigue as the symptoms that shape daily life most, with cough, chest tightness, and difficulty sleeping also common.10PubMed Central. “Getting stuck with LAM”: patients perspectives on living with Lymphangioleiomyomatosis
Beyond the lungs, the disease leaves footprints across the abdomen. In one study of 80 patients, about three quarters had at least one abdominal finding on imaging. Renal angiomyolipomas showed up in over half, enlarged lymph nodes in roughly 40%, and cystic lymphatic masses in about one in six. Less common findings included fluid in the abdomen and a dilated thoracic duct.11PubMed. Lymphangioleiomyomatosis: abdominopelvic CT and US findings Renal angiomyolipomas are usually small and harmless, but they can occasionally grow large enough to bleed, which is a medical emergency.
Getting to a Diagnosis
LAM is often diagnosed years after symptoms begin. A study of over 500 patients found an average ten-year gap between when symptoms first appeared and when the diagnosis was finally made.12PubMed Central. Educational attainment of individuals with lymphangioleiomyomatosis is a determinant of timely diagnosis and treatment uptake Much of this delay happens because a young woman showing up with a collapsed lung or unexplained breathlessness does not immediately make a doctor think of a disease most of them have only read about in a textbook. The same study found that women with a bachelor’s degree were diagnosed nearly five years earlier than those without one, likely reflecting differences in access, health literacy, and willingness to push for further evaluation.
When LAM is suspected, high-resolution CT scanning of the chest is the cornerstone. The hallmark is multiple thin-walled, round, air-filled cysts scattered evenly throughout both lungs, with no other major lung abnormality. A scan showing more than ten such cysts in the right clinical context is considered characteristic.13European Respiratory Review. Lymphangioleiomyomatosis: what do we know and what are we looking for? Abdominal imaging showing renal angiomyolipomas or lymphatic masses adds corroborating evidence.14PubMed. Lymphangioleiomyomatosis: pulmonary and abdominal findings with pathologic correlation
A blood test for a protein called VEGF-D has become a valuable non-invasive diagnostic tool. In a meta-analysis, the test showed pooled sensitivity of about 82% and specificity around 98%, meaning a high VEGF-D level is very strong evidence for LAM, though a normal level does not rule it out.15PubMed Central. Diagnostic performance of VEGF-D for lymphangioleiomyomatosis: a meta-analysis In prospective testing, VEGF-D levels above 800 pg/mL were essentially diagnostic, while every patient later found to have a different cystic lung disease had levels below 600 pg/mL.16PubMed Central. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases When imaging and VEGF-D together point strongly to LAM, many patients can be spared a surgical lung biopsy.
Distinguishing LAM from Other Cystic Lung Diseases
Several other conditions produce lung cysts on CT, and telling them apart matters because the treatments are completely different. Birt-Hogg-Dubé syndrome is probably the closest mimic, but its cysts tend to be oval or lenticular rather than perfectly round, cluster in the lower lung zones rather than being evenly distributed, and affect men and women equally.17Polish Journal of Radiology. Familial pneumothoraces – Birt-Hogg-Dubé syndrome. Differentiation with other cystic lung diseases Pulmonary Langerhans cell histiocytosis and lymphoid interstitial pneumonia also cause cysts but bring different clinical patterns. Certain clinical features can settle the question quickly: lymphatic involvement or renal angiomyolipomas were found exclusively in LAM patients in one comparative study, while the presence of connective tissue disease or related antibodies pointed exclusively to lymphoid interstitial pneumonia.18Annals of the American Thoracic Society. Utility of Presenting Features to Differentiate between Rare Cystic Lung Diseases
Sirolimus Changed the Treatment Landscape
Before sirolimus, there was no drug therapy for LAM that worked consistently. Because the disease is driven by an overactive mTORC1 pathway, sirolimus (also known as rapamycin), which directly inhibits that pathway, was a logical candidate. The pivotal randomized trial confirmed the logic: patients on placebo lost lung function at a rate of about 12 mL per month, while patients on sirolimus held essentially steady, gaining about 1 mL per month. The gap translated to roughly 153 mL of preserved lung capacity over the treatment year, along with improvements in quality of life and exercise tolerance.19PubMed Central. Efficacy and safety of sirolimus in lymphangioleiomyomatosis After stopping the drug, however, lung function began declining again at the same rate as in untreated patients, indicating that sirolimus suppresses rather than cures the disease.
An observational study before that trial had already signaled this pattern. In patients tracked for an average of two and a half years before and after starting sirolimus, lung function went from declining by about 2.8% predicted per year to improving by about 1.8% predicted per year. Patients who had chylous effusions or lymphatic masses saw near-complete resolution of those problems.20PubMed Central. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus Longer-term data from a single referral center found that about 59% of sirolimus-treated patients maintained improved lung function over five years, while others stabilized or continued to decline at a reduced rate. Renal angiomyolipomas also responded, with the vast majority shrinking during the first year of treatment.21PubMed Central. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience
Sirolimus is not without side effects. Mouth sores, acne, elevated cholesterol, and an increased susceptibility to infections are all recognized issues. Despite those drawbacks, most patients tolerate the drug well enough to stay on it long term, and it remains the only drug with strong trial evidence for LAM. Only about 53% of diagnosed patients in one large survey reported using an mTOR inhibitor, which suggests that access, awareness, and side-effect concerns still limit uptake.12PubMed Central. Educational attainment of individuals with lymphangioleiomyomatosis is a determinant of timely diagnosis and treatment uptake
Managing Pneumothorax
A collapsed lung is sometimes the very first sign of LAM, and it tends to come back. Left untreated with just observation and chest drainage, the recurrence rate was about 66% in one large study. Both chemical pleurodesis (instilling a substance to seal the lung lining) and surgical pleurodesis brought that rate down to roughly 27-32%.22PubMed. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications Given that high recurrence rate, guidelines from the American Thoracic Society recommend considering pleurodesis after even the first pneumothorax rather than waiting for a recurrence, and they advise against using a history of pleurodesis as grounds to deny someone a future lung transplant.23PubMed Central. Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management
Chylous pleural effusions, caused by leaking lymphatic fluid, are another recurring complication. Management strategies range from pleurodesis to thoracic duct ligation and embolization, with tunneled indwelling pleural catheters used for cases that resist other approaches.24PubMed. Surgical management of pleural complications in lymphangioleiomyomatosis
Pregnancy and LAM
Because LAM targets women during their reproductive years, the question of whether pregnancy is safe comes up constantly. The honest answer is that it is risky but not impossible. Estrogen surges during pregnancy can accelerate the disease, and about 30% of pregnancies in women already diagnosed with LAM developed LAM-related complications including worsening breathlessness, pneumothorax, and spontaneous bleeding from renal angiomyolipomas. Women who were on sirolimus before becoming pregnant appeared to face a higher risk of miscarriage.25PubMed Central. Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM) Patients diagnosed with LAM for the first time during pregnancy tend to have worse outcomes than those who were already known and monitored.26PubMed Central. Lymphangioleiomyomatosis and pregnancy: a mini-review None of this means that women with LAM cannot have children, but the decision requires close consultation with a specialist team that can weigh the individual’s disease severity against her reproductive goals.
Living with LAM Day to Day
The psychological burden of LAM often gets less attention than the lung function numbers, but patients rank it as profoundly significant. Frustration, worry, and a sense of lost identity are commonly reported emotional themes. Embarrassment about visible symptoms like breathlessness and the need for supplemental oxygen adds to the toll.10PubMed Central. “Getting stuck with LAM”: patients perspectives on living with Lymphangioleiomyomatosis In a cross-sectional study of 45 women with LAM, roughly a third screened positive for anxiety and about one in six for depression. The domains that scored lowest on quality-of-life measures were general health, vitality, breathlessness, and fatigue.27PubMed. Clinical and Functional Outcomes Associated with Quality of Life in Patients with Lymphangioleiomyomatosis: A Cross-Sectional Study A larger study of 87 patients found even higher rates: anxiety in 46% and depression in 55%. The same study identified resilience, spirituality, and strong social support as protective factors against psychological distress.28Open Respiratory Archives. A Study on the Psychological Profile and Coping With the Disease in Patients With Lymphangioleiomyomatosis
Pulmonary rehabilitation has proven to be a genuine bright spot. A controlled trial found that LAM patients who completed a rehabilitation program gained meaningful improvements in exercise endurance, walking distance, breathlessness, daily physical activity, and muscle strength without any serious adverse events.29PubMed. Pulmonary rehabilitation in lymphangioleiomyomatosis: a controlled clinical trial Even patients with advanced disease benefit. A retrospective study of 58 women with severely reduced lung function found that a four-week inpatient rehabilitation program improved walking distance by an average of 49 meters and boosted mental quality-of-life scores, with gains comparable to what is seen in COPD patients going through the same programs.30PubMed Central. Benefits of pulmonary rehabilitation in patients with advanced lymphangioleiomyomatosis (LAM) compared with COPD – a retrospective analysis Yoga-based rehabilitation has also been explored as a safe, feasible option for improving exercise capacity.31PubMed Central. Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study
Lung Transplantation
For women whose lung function continues to deteriorate despite sirolimus and supportive care, lung transplant remains an option. European transplant data showed one-year survival of 79% and three-year survival of 73%, which is broadly comparable to outcomes for other lung diseases requiring transplant.32PubMed. Lung transplantation for lymphangioleiomyomatosis: the European experience One complication unique to LAM is that the disease can recur in the transplanted lungs. It is uncommon, and when it happens, it tends to appear years later, but its very existence reflects LAM’s nature as a systemic rather than purely pulmonary disease. A published case described recurrence nine years after bilateral transplant.33PubMed Central. Recurrence of lymphangioleiomyomatosis: Nine years after a bilateral lung transplantation Post-transplant chylous effusions can also occur, reinforcing the need for ongoing monitoring even after surgery.
What Comes After Sirolimus
Sirolimus holds the disease in check for many patients, but it does not work for everyone, it does not cure anyone, and it carries side effects that some find hard to tolerate over the decades of treatment a young woman might need. That reality has fueled a pipeline of experimental approaches. Clinical trials have investigated drugs targeting autophagy, tyrosine kinase receptors, and hormonal pathways. Newer avenues being explored in preclinical and early clinical work include targeting the immune environment around LAM cells, histamine signaling, and a family of enzymes called Src kinases.34PubMed Central. Novel treatment strategies for lymphangioleiomyomatosis: a narrative review Research into additional targets downstream of the mTORC1 pathway, particularly in the machinery that controls protein production inside LAM cells, has also highlighted potential drug targets that current therapy does not fully address.1PubMed Central. Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis The field’s hope is that combining mTOR inhibition with a second agent attacking the disease from a different angle could push outcomes beyond what sirolimus achieves alone.